Please assess the completion status of the following clinical trial:

Trial Title: Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* BMI above or equal to 25 and below or equal to 40 kg/m\^2~* Subjects diagnosed with T2D (Type 2 diabetes) treated with diet and exercise and/or who have been on a stable dose of metformin for at least 30 days prior to screening~* HbA1c 7.0-9.5% (53-80 mmol/mol) (both inclusive)~Exclusion Criteria:~* Subjects on selected oral medication with a narrow therapeutic window, such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and anticonvulsants~* History of chronic pancreatitis or idiopathic acute pancreatitis~* Chronic malabsorption, regardless of aetiology~* History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease~* Treatment with glucose lowering agent(s) other than metformin as stated in the inclusion criteria in a period of 90 days before the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1:Semaglutide tablets : 2.5 mg (Type: EXPERIMENTAL): 2.5 mg for 26 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
- 2:Semaglutide tablets: 2.5 mg/5 mg (Type: EXPERIMENTAL): 2.5 mg for 4 weeks, then 5.0 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
- 3:Semaglutide tablets: 5.0 mg/10 mg (Type: EXPERIMENTAL): 5.0 mg for 4 weeks, then 10 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
- 4:Semaglutide tablets:5.0 mg/10 mg/20 mg (Type: EXPERIMENTAL): 5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
- 5:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg (Type: EXPERIMENTAL): 5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
- 6:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg (Type: EXPERIMENTAL): 5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
- 7:Semaglutide tablets: 5.0 mg/10 mg/20 mg/40 mg (Type: EXPERIMENTAL): 5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
- 8:Placebo tablets (Type: PLACEBO_COMPARATOR): All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
- 9:Semaglutide injections :0.25 mg/0.50 mg/1.0 mg (Type: ACTIVE_COMPARATOR): 0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).